Oral fluconazole single dose seems to be a valid and promising therapy to cure acute signs and symptoms of VVC.
Introduction
Vulvovaginal candidiasis(VVC) is a lower genital tract disorder that occurs in 75% of women at least once in their lifetime with 40 -50% of women experiencing a second attack. [1] . Candida albicans is the species most often associated with VVC, however, other yeasts can also cause this infection. VVC is treated with a variety of anti-fungal drugs [2] . Frequent recurrences of symptomatic vulvovaginitis result in considerable suffering and cost and have a markedly negative effect on sexual relations [3] . Diagnosis is made by vaginal fluid specimen, microscopic examination and culture [4] . Currently available options for the treatment of this condition include antifugal agents.
There are variety of effective treatments that include topical or oral antifungals. Topical azoles are used for 1, 3, 7, or even 14 days, whereas oral drugs are recommended to be used for 1, 3 or 5 days [5] . An ideal antifugal drug should be easy to administer, effective in short therapy, with a broad spectrum of treatment, causing complete eradication, preventing recurrent infections, bringing relief to patients, without side effects, inexpensive and safe to administer during pregnancy [6] . A metaanalysis study showed that there was no significant difference regarding the effectiveness between oral and topical treatment of uncomplicated VVC [5] . Although topical regimens are commonly, used oral treatment is preferred by patients because of the ease of administration and the reduced duration of use [7] .
fluconazole is a triazole antifungal agent introduced in the early 1990s which has a good safety profile and is the most widely used antifungal agent for VVC. The mechanism of action of the group of azole antifungals is the inhibition of the fungal cytochrome P450 oxidase-mediated synthesis of ergosterol, which is an essential component of the fungal cytoplasmic membrane. The susceptibility of candida species to fluconazole, however, is not uniform. Candida albicans is highly susceptible to fluconazole [8] and [9] . Table 1 shows that there was no difference in the demographic characteristics of both study groups. Table 2 shows that on the first visit candida was clinically treated in 53 (73.6%) patients in the fluconazole group and 41 (58.6%) in the clotrimazole group and also eradicated (culture was negative) in 60 (83.3%) of patients in the fluconazole group and in 49 (70%) in the clotrimazole group (P = 0.001).
There was no difference in side effects in two groups (p = 0.4). The major drug complication in fluconazole group was headache and in clotrimazole group it was pelvic pain. In Table 3 the recurrence of VVC after one month of treatment was reported. At the third visit (one month) candida was recurrent symptomatically in 1 patient in the fluconazole group and 17 patients in clotrimazole group (P = 0.001). Mycological symptoms were positive in 1 patient in the fluconazole group and 7 patients in clotrimazole group at the same time (P = 0.01) More than 97% patients enrolled in the study would prefer oral fluconazole treatment compared to topical clotrimazole 68.6% (P = 0.001).
Discussion
Over the past two decades, the imidazoles (miconazole, clotrimazole 
Conclusion
This study showed that single dose oral fluconazole is more effective than conventional topical clotrimazole for seven days in the treatment of acute VVC. Fluconazole can more successfully and safely cure clinical and micrological symptom of VVC than clotrimazole and can be more effective in reduction of the relapse rate of the disease than clotrimazole. A long-term cure, however remains elusive. . 
